EU Approves New Use for Regeneron's EYLEA

EU Approves New Use for Regeneron's EYLEA

Regeneron Pharmaceuticals announced today that the European Commission has approved its EYLEA injection for an additional type of visual impairment, expanding the reach of EYLEA's applicability.

"We are pleased with the approval of EYLEA in the E.U. in a second indication," said Dr. George Yancopoulos, chief scientific officer of Regeneron and president of Regeneron Laboratories, in a statement today. "Our Phase 3 studies showed that EYLEA improved visual outcomes significantly in macular edema following [central retinal vein occlusion] CRVO. This additional approval of EYLEA is great news for patients in Europe suffering from macular edema following CRVO, a debilitating disease affecting central vision."

Macular edema causes swelling and blurred vision. Central retinal vein occlusion is caused by the obstruction of the central retinal vein that leads to a backup of blood and fluid in the retina, which causes vision loss.

The drug was developed in collaboration with Bayer HealthCare, and the two companies will split European profits 50/50, while Regeneron maintains exclusive rights in the United States.

According to Regeneron, around 66,000 Europeans suffer from CRVO. The drug was approved for similar treatments in the U.S. in September 2012, where an estimated 100,000 Americans are affected by CRVO.

-- Material from The Associated Press was used in this report.


The article EU Approves New Use for Regeneron's EYLEA originally appeared on

Fool contributor Justin Loiseau has no position in any stocks mentioned. You can follow him on Twitter, @TMFJLo, and on Motley Fool CAPS, @TMFJLo.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.